These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 28529308)

  • 1. Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.
    Falchi L; Kantarjian HM; Verstovsek S
    Leukemia; 2017 Sep; 31(9):1845-1854. PubMed ID: 28529308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study.
    Pérez Encinas MM; Sobas M; Gómez-Casares MT; Abuin Blanco A; Noya Pereira MS; Raya JM; Andrade-Campos MM; Álvarez Larrán A; Lewandowski K; Łukasz S; Hernández Boluda JC; Ferrer-Marín F; Fox ML; Gołos A; Gasior Kabat M; Magro Mazo E; Czyż A; Martín Martín A; Bellosillo Paricio B; Quinteiro García C; González Martín JM; Stuckey R
    Eur J Haematol; 2021 Mar; 106(3):371-379. PubMed ID: 33275803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history.
    Gangat N; Wassie EA; Lasho TL; Finke C; Ketterling RP; Hanson CA; Pardanani A; Wolanskyj AP; Maffioli M; Casalone R; Passamonti F; Tefferi A
    Eur J Haematol; 2015 Jan; 94(1):31-6. PubMed ID: 24889737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematological relevance of JAK2 V617F and calreticulin mutations in Tunisian patients with essential thrombocythemia.
    Abdelghani M; Hammami H; Zidi W; Amouri H; Othmen HBH; Farrah A; Menif S
    J Clin Lab Anal; 2022 Aug; 36(8):e24522. PubMed ID: 35754115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatic mutations of calreticulin in myeloproliferative neoplasms.
    Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
    N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Furuya C; Hashimoto Y; Morishita S; Inano T; Ochiai T; Shirane S; Edahiro Y; Araki M; Ando M; Komatsu N
    Hematology; 2023 Dec; 28(1):2229131. PubMed ID: 37378567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombotic risk correlates with mutational status in true essential thrombocythemia.
    Bertozzi I; Peroni E; Coltro G; Bogoni G; Cosi E; Santarossa C; Fabris F; Randi ML
    Eur J Clin Invest; 2016 Aug; 46(8):683-9. PubMed ID: 27271054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between thrombotic risk scores in essential thrombocythemia and survival implications.
    Santoro M; Accurso V; Mancuso S; Carlisi M; Raso S; Tarantino G; Di Piazza F; Perez A; Russo A; Siragusa S
    Hematol Oncol; 2019 Oct; 37(4):434-437. PubMed ID: 31465530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the effects between MPL and JAK2V617F on thrombosis and peripheral blood cell counts in patients with essential thrombocythemia: a meta-analysis.
    Yang E; Wang M; Wang Z; Li Y; Wang X; Ming J; Xiao H; Quan R; Liu W; Hu X
    Ann Hematol; 2021 Nov; 100(11):2699-2706. PubMed ID: 34383101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations.
    Okabe M; Yamaguchi H; Usuki K; Kobayashi Y; Kawata E; Kuroda J; Kimura S; Tajika K; Gomi S; Arima N; Mori S; Ito S; Koizumi M; Ito Y; Wakita S; Arai K; Kitano T; Kosaka F; Dan K; Inokuchi K
    Leuk Res; 2016 Jan; 40():68-76. PubMed ID: 26614694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombotic Prediction Model Based on Epigenetic Regulator Mutations in Essential Thrombocythemia Patients Using Survival Analysis in Recurrent Events.
    Saelue P; Sinthujaroen P; Suwiwat S; Thongsuksai P
    Clin Appl Thromb Hemost; 2024; 30():10760296241263099. PubMed ID: 39053144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.
    Alvarez-Larrán A; Pereira A; Guglielmelli P; Hernández-Boluda JC; Arellano-Rodrigo E; Ferrer-Marín F; Samah A; Griesshammer M; Kerguelen A; Andreasson B; Burgaleta C; Schwarz J; García-Gutiérrez V; Ayala R; Barba P; Gómez-Casares MT; Paoli C; Drexler B; Zweegman S; McMullin MF; Samuelsson J; Harrison C; Cervantes F; Vannucchi AM; Besses C
    Haematologica; 2016 Aug; 101(8):926-31. PubMed ID: 27175028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia.
    Hsiao HH; Yang MY; Liu YC; Lee CP; Yang WC; Liu TC; Chang CS; Lin SF
    Exp Hematol; 2007 Nov; 35(11):1704-7. PubMed ID: 17920754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microparticle phenotypes are associated with driver mutations and distinct thrombotic risks in essential thrombocythemia.
    Charpentier A; Lebreton A; Rauch A; Bauters A; Trillot N; Nibourel O; Tintillier V; Wemeau M; Demory JL; Preudhomme C; Jude B; Lecompte T; Cambier N; Susen S
    Haematologica; 2016 Sep; 101(9):e365-8. PubMed ID: 27247323
    [No Abstract]   [Full Text] [Related]  

  • 15. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms.
    Guo H; Chen X; Tian R; Chang J; Li J; Tan Y; Xu Z; Ren F; Zhao J; Pan J; Zhang N; Wang X; He J; Yang W; Wang H
    PLoS One; 2015; 10(9):e0138250. PubMed ID: 26375990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. It is time to change thrombosis risk assessment for PV and ET?
    Passamonti F; Caramazza D; Mora B; Casalone R; Maffioli M
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):121-7. PubMed ID: 25189723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of JAK2V617F mutation on different types of thrombosis risk in patients with essential thrombocythemia: a meta-analysis.
    Qin Y; Wang X; Zhao C; Wang C; Yang Y
    Int J Hematol; 2015 Aug; 102(2):170-80. PubMed ID: 25997869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Essential thrombocythemia: baseline characteristics and risk factors for survival and thrombosis in a series of 214 patients].
    Angona A; Alvarez-Larrán A; Bellosillo B; Martínez-Avilés L; Garcia-Pallarols F; Longarón R; Ancochea À; Besses C
    Med Clin (Barc); 2015 Mar; 144(6):247-53. PubMed ID: 25192581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK2V617F mutation and circulating extracellular vesicles in essential thrombocythemia.
    Aswad MH; Kissova J; Ovesna P; Říhová L; Penka M
    Clin Hemorheol Microcirc; 2023; 84(4):359-368. PubMed ID: 37334581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.